2 assets in Mitochondrial Encephalomyopathy

Therapeutic assets addressing Mitochondrial Encephalomyopathy, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione Mitochondrial Encephalomyopathy	Kenneth Myers, MD	P2	CCC (53)
Doxecitine Mitochondrial Encephalomyopathy	Kenneth Myers, MD	P2	CCC (53)